Ketoconazole inhibition of the bifunctional cytochrome P450c17 does not affect androgen formation from the endogenous lyase substrate. The catalytic site remains refractory in the course of intermediary hydroxyprogesterone processing.
The inhibition of the bifunctional steroidogenic cytochrome P450c17 (CYP17: steroid-17 alpha-hydroxylase/steroid-17,20-lyase) by the imidazole-type fungicide, [(+/-)-cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl- methyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine) (ketoconazole), was investigated with the aim of differentiating between effects on androgen formation from exogenously added and endogenously produced 17 alpha-hydroxyprogesterone. Using microsomal membranes from rat testis, turnover of progesterone by P450c17 was competitively inhibited by ketoconazole with KI = 0.40 microM. Ketoconazole did not affect the linear relationship between the ratio of productive events (corresponding to androgen formation rates) versus abortive events (corresponding to 17 alpha-hydroxyprogesterone formation rates) and the sum of catalytic events. This was an indication that this inhibitor did not interfere with intermediate processing by P450c17. Androgen formation from exogenous but not from endogenous 17 alpha-hydroxyprogesterone was competitively inhibited by ketoconazole. The simultaneous conversion of 1 microM each of [3H]progesterone and 17 alpha-hydroxy[14C]progesterone was also reduced by ketoconazole. Calculation of 3H/14C ratios in the 17 alpha-hydroxyprogesterone and androgen fractions revealed that the endogenous 17 alpha-hydroxyprogesterone pool was metabolized to androgens at rates 6.4, 11.6, 17.6 and 21.2-fold faster than the exogenous pool in the presence of 0.5, 1, 2 and 4 microM ketoconazole, respectively; this value was only 4.0 in controls. It is concluded that ketoconazole inhibits turnover of steroid ligands only when they approach the P450c17 active site in a substrate-state and that inhibition of androgen formation from progesterone is due to inhibition of the first catalytic step only. A model is described in which the P450c17 active site is refractory towards ketoconazole when the intermediary steroid is retained and being processed at that site.
Kühn-Velten
W N
WN
Department of Obstetrics and Gynecology, Heinrich-Heine-Universität, Düsseldorf, Federal Republic of Germany.
Lessmann
M
M
D019326:17-alpha-Hydroxyprogesterone; D000446:Aldehyde-Lyases / Q000037:antagonists & inhibitors*; D000728:Androgens / Q000096:biosynthesis*; D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D065607:Cytochrome P-450 Enzyme Inhibitors; D006908:Hydroxyprogesterones / Q000378:metabolism* / Q000494:pharmacology; D007425:Intracellular Membranes / Q000378:metabolism; D007654:Ketoconazole / Q000494:pharmacology*; D008297:Male; D011374:Progesterone / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013254:Steroid 17-alpha-Hydroxylase; D013737:Testis / Q000378:metabolism
D000728:Androgens; D065607:Cytochrome P-450 Enzyme Inhibitors; D006908:Hydroxyprogesterones; D011374:Progesterone; D019326:17-alpha-Hydroxyprogesterone; D013254:Steroid 17-alpha-Hydroxylase; D000446:Aldehyde-Lyases; D007654:Ketoconazole